These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 10395703)

  • 21. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection.
    Lebens M; Sun JB; Sadeghi H; Bäckström M; Olsson I; Mielcarek N; Li BL; Capron A; Czerkinsky C; Holmgren J
    Vaccine; 2003 Jan; 21(5-6):514-20. PubMed ID: 12531651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-10 is crucial for the transition from acute to chronic disease state during infection of mice with Schistosoma mansoni.
    Sadler CH; Rutitzky LI; Stadecker MJ; Wilson RA
    Eur J Immunol; 2003 Apr; 33(4):880-8. PubMed ID: 12672053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
    El Ridi R; Tallima H
    Vaccine; 2009 Jan; 27(5):666-73. PubMed ID: 19056448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine.
    Tarkowski A; Sun JB; Holmdahl R; Holmgren J; Czerkinsky C
    Arthritis Rheum; 1999 Aug; 42(8):1628-34. PubMed ID: 10446861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schistosoma mansoni in mice: the pattern of primary cercarial exposure determines whether a secondary infection post-chemotherapy elicits a T helper 1- or a T helper 2-associated immune response.
    Farah IO; Johansson M; Lövgren-Bengtson K; Hau J
    Scand J Immunol; 2000 Mar; 51(3):237-43. PubMed ID: 10736092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of a Schistosoma mansoni 28-kilodalton glutathione S-transferase in the livers of transgenic mice and its effect on parasite infection.
    Xu X; Lemaire C; Grzych JM; Pierce RJ; Raccurt M; Mullier F; Zerimech F; Decavel JP; Peyrol S; Liu J; Fontaine J; Lafitte S; Capron A; Cesbron JY
    Infect Immun; 1997 Sep; 65(9):3867-74. PubMed ID: 9284165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diminished immunopathology in Schistosoma mansoni infection following intranasal administration of cholera toxin B-immunodominant peptide conjugate correlates with enhanced transforming growth factor-beta production by CD4 T cells.
    Hernandez HJ; Rutitzky LI; Lebens M; Holmgren J; Stadecker MJ
    Parasite Immunol; 2002 Aug; 24(8):423-7. PubMed ID: 12406196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
    Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
    Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni.
    Boulanger D; Reid GD; Sturrock RF; Wolowczuk I; Balloul JM; Grezel D; Pierce RJ; Otieno MF; Guerret S; Grimaud JA
    Parasite Immunol; 1991 Sep; 13(5):473-90. PubMed ID: 1956696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J; Adamsson J; Harandi AM
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment.
    Dupré ; Herv M; Schacht AM; Capron A; Riveau G
    J Infect Dis; 1999 Aug; 180(2):454-63. PubMed ID: 10395862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile.
    Jankovic D; Kullberg MC; Noben-Trauth N; Caspar P; Ward JM; Cheever AW; Paul WE; Sher A
    J Immunol; 1999 Jul; 163(1):337-42. PubMed ID: 10384133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Schistosoma mansoni antigens recognized by T cells of C57BL/6 mice immunized with gamma-irradiated cercariae.
    Osman A; el Ridi R; Guirguis N; Dean DA
    J Parasitol; 1994 Jun; 80(3):421-31. PubMed ID: 8195944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation.
    Actor JK; Marshall MA; Eltoum IA; Buller RM; Berzofsky JA; Sher A
    Eur J Immunol; 1994 Dec; 24(12):3050-6. PubMed ID: 7805733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis.
    Cheever AW; Williams ME; Wynn TA; Finkelman FD; Seder RA; Cox TM; Hieny S; Caspar P; Sher A
    J Immunol; 1994 Jul; 153(2):753-9. PubMed ID: 8021510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasciola gigantica and Schistosoma mansoni: vaccine potential of recombinant glutathione S-transferase (rFgGST26) against infections in mice.
    Preyavichyapugdee N; Sahaphong S; Riengrojpitak S; Grams R; Viyanant V; Sobhon P
    Exp Parasitol; 2008 Jun; 119(2):229-37. PubMed ID: 18329021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to the fucosylated LacdiNAc glycan antigen in Schistosoma mansoni-infected mice and expression of the glycan among schistosomes.
    Nyame AK; Leppänen AM; Bogitsh BJ; Cummings RD
    Exp Parasitol; 2000 Dec; 96(4):202-12. PubMed ID: 11162373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of cytotoxic T-cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C-terminal lipopeptide.
    Pancré V; Gras-Masse H; Delanoye A; Herno J; Capron A; Auriault C
    Scand J Immunol; 1996 Nov; 44(5):485-92. PubMed ID: 8947600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IFN-gamma, IL-12, and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12.
    Hoffmann KF; Caspar P; Cheever AW; Wynn TA
    J Immunol; 1998 Oct; 161(8):4201-10. PubMed ID: 9780194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization with SmIg, a novel tegument protein from Schistosoma mansoni, fails to induce protection in mice but reduces liver pathology.
    Pinho JM; Cardoso FC; Lopes DO; Pinheiro CS; Caliari MV; Oliveira FM; Leite LC; Oliveira SC
    Parasitology; 2010 Jun; 137(7):1079-88. PubMed ID: 19835649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.